Physician profile
Susan Raschal
NPI 1063451813
$39,989.14
in general payments reported to CMS, 2019-2025
42 companies · $3,370 in 2025
The $3,370 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,931 · 2020: $2,916 · 2021: $3,363 · 2022: $11K · 2023: $8,889 · 2024: $7,071 · 2025: $3,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $6,637 · Consulting Fee: $64.34 · Travel and Lodging: $16.80 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,600.00 |
| Food and Beverage | $6,636.84 |
| Consulting Fee | $64.34 |
| Travel and Lodging | $16.80 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,194.08 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $3,226.72 | 2021-2024 | Tezspire |
| Glaxosmithkline, LLC. | $1,824.03 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,798.33 | 2019-2025 | |
| Csl Behring | $1,755.07 | 2019-2025 | Haegarda, Hizentra |
| Regeneron Healthcare Solutions, INC. | $1,295.35 | 2019-2025 | Dupixent |
| Optinose US, INC. | $936.02 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $673.55 | 2020-2024 | Hyqvia, Cuvitru, Takhzyro |
| Grifols USA, LLC | $547.82 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Pfizer INC. | $495.34 | 2019-2024 | |
| Biocryst US Sales Co., LLC | $447.65 | 2021-2025 | Orladeyo |
| Abbvie INC. | $404.40 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.27 | 2019-2023 | Spiriva Respimat |
| Genentech USA, INC. | $278.66 | 2019-2025 | Xolair |
| Kaleo, INC. | $271.59 | 2019-2024 | Auvi-Q |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $236.86 | 2019-2022 | |
| Pharming Healthcare, INC. | $229.58 | 2022-2025 | Ruconest |
| Alk-Abello, INC | $225.37 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Mylan Specialty L.P. | $221.55 | 2019-2024 | Yupelri |
| Octapharma USA, INC. | $220.40 | 2021-2024 | Cutaquig |
| Incyte Corporation | $181.13 | 2021-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $162.76 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $152.29 | 2019-2020 | |
| Organon LLC | $141.11 | 2025 | Vtama |
| Insmed, INC. | $140.00 | 2025 | Brinsupri |
| Adma Biomanufacturing LLC | $99.32 | 2021-2024 | |
| Shire North American Group INC | $82.09 | 2019 | |
| Cycle Pharmaceuticals INC | $60.35 | 2024-2025 | Sajazir |
| Leo Pharma INC. | $53.53 | 2022-2023 | Adbry |
| Gc Biopharma USA, INC. | $46.98 | 2024-2025 | Alyglo, Alyglo |
| Blueprint Medicines Corporation | $40.54 | 2022 | |
| Greer Laboratories, INC. | $31.64 | 2019 | |
| Circassia INC. | $31.49 | 2019 | |
| Merck Sharp & Dohme LLC | $30.83 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $28.76 | 2024 | Ryaltris |
| Verona Pharma, INC. | $21.73 | 2025 | Ohtuvayre |
| Ars Pharmaceuticals Operations, INC. | $19.67 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $18.16 | 2024 | |
| Horizon Therapeutics Plc | $18.05 | 2019 | |
| Lilly USA, LLC | $17.56 | 2025 | Ebglyss |
| Uswm, LLC | $15.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Raschal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.